Chronic Myeloid Leukemia Face-Off: Kendra Sweet, MD, on Updates in Ponatinib and Asciminib

EP. 1: How Ponatinib Factors into the Treatment of a Type of Leukemia

December 23rd 2022

Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.

EP. 2: The Implications of CML Data From ASH, And Important Takeaways for Providers

December 24th 2022

Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.

EP. 3: Highlighting Ongoing Clinical Trials in CML From ASH

December 26th 2022

Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.